GlassScriptPhysician profile
Jayesh K Parikh
NPI 1932142981
$4,999.56
in general payments reported to CMS, 2019-2025
21 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $323 · 2021: $265 · 2022: $658 · 2023: $909 · 2024: $1,280 · 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,365 · Education: $14.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,364.61 |
| Education | $14.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,489.32 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,126.87 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $388.08 | 2019-2025 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Genzyme Corporation | $208.91 | 2024-2025 | |
| Mylan Specialty L.P. | $170.25 | 2020-2024 | Yupelri |
| Silk Road Medical, INC. | $122.04 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Becton, Dickinson and Company | $120.81 | 2024 | Phasix Mesh |
| Boston Scientific Corporation | $78.05 | 2023 | Watchman Flx |
| Insmed, INC. | $49.26 | 2025 | Arikayce, Brinsupri |
| Philips North America LLC | $47.91 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $40.32 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $26.29 | 2020-2023 | |
| Verona Pharma, INC. | $15.75 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $15.68 | 2025 | Yupelri |
| Lilly USA, LLC | $15.05 | 2025 | Zepbound |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $14.99 | 2025 | Dupixent |
| Allergan, INC. | $14.96 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.78 | 2019 | |
| Genentech USA, INC. | $14.45 | 2019 | |
| Paratek Pharmaceuticals, INC. | $14.15 | 2020 | |
| Circassia INC. | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayesh Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.